Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Donaueschingen – page 41

591 clinical trials in Donaueschingen, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Donaueschingen at a glance
591
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

591 trials in Donaueschingen

Open in trial search

Plasma cell myeloma

Not recruiting

Study of Venetoclax, Daratumumab, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Plasma cell myeloma

Not recruiting

Study Comparing ABBV-383 with Standard Therapies for Adults with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on the Effects of Triheptanoin and Medium-chain Triglycerides in Children with Long-chain Fatty Acid Oxidation Disorders

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Doconexent
  • Sponsor:Ultragenyx Pharmaceutical Inc.

Myelofibrosis+1

Not recruiting

Study on the Safety and Effects of Navitoclax and Ruxolitinib for Patients with Myelofibrosis and Myeloproliferative Neoplasms

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Celecoxib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study of Danicopan for Patients with Geographic Atrophy Due to Age-Related Macular Degeneration

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Danicopan
  • Sponsor:Alexion Pharmaceuticals Inc.

Adenocarcinoma gastric+1

Not recruiting

Study of Pembrolizumab with Chemotherapy for Patients with Gastric or Gastroesophageal Junction Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Calcium Folinate
  • Sponsor:Merck Sharp & Dohme LLC

Study on the Effects of Vidofludimus Calcium for Patients with Post-COVID Syndrome

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Vidofludimus Calcium
  • Sponsor:Goethe University Frankfurt

Study on the Safety and Effectiveness of Bezuclastinib for Patients with Advanced Systemic Mastocytosis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bezuclastinib
  • Sponsor:Cogent Biosciences Inc.

Study of Tamibarotene and Azacitidine Treatment in Newly Diagnosed Adults with RARA-positive Higher-risk Myelodysplastic Syndrome (MDS)

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Syros Pharmaceuticals Inc.

Study on the Effectiveness and Safety of Ralinepag for Patients with Pulmonary Arterial Hypertension

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ralinepag
  • Sponsor:United Therapeutics Corp.

Study on the Effectiveness and Safety of Depemokimab vs. Mepolizumab for Adults with Relapsing or Refractory Eosinophilic Granulomatosis with Polyangiitis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Pulmonary embolism

Not recruiting

Study on Reduced Dose of Alteplase for Patients with Intermediate-High-Risk Acute Pulmonary Embolism

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Alteplase
  • Sponsor:Assistance Publique Hopitaux De Paris

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Donaueschingen

What the registry says about research in the country

01 Pulmonary Research

Groundbreaking clinical trials focusing on pulmonary arterial hypertension (PAH) are exploring innovative treatment approaches. The research aims to evaluate new therapeutic interventions for patients dealing with this challenging cardiovascular condition.

  • Treatment Efficacy Assessment
  • Safety Profile Evaluation
  • Clinical Progression Monitoring

These studies are designed to track and assess clinical outcomes in PAH patients, with particular attention to preventing disease progression and improving patient well-being.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.